Education
About Us
Working with TipRanks
Follow Us
IGM Biosciences Inc (IGMS)
NASDAQ:IGMS
IGMS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.15 - $22.50
Previous CloseN/A
Volume43.44K
Average Volume (3M)223.34K
Market Cap
$73.52M
Enterprise Value$830.16M
Total Cash (Recent Filing)$26.50M
Total Debt (Recent Filing)$45.19M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Mar 27, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.25
Shares Outstanding34,388,420
10 Day Avg. Volume191,871
30 Day Avg. Volume223,344
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)26.55
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap11.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit309.88
Enterprise Value/Ebitda-4.16
Forecast
1Y Price Target
$2.18Price Target Upside77.24% Upside
Rating ConsensusHold
Number of Analyst Covering8
---
IGM Biosciences News
PremiumCompany Announcements
IGM Biosciences Halts Antibody Therapies, Cuts Workforce
---
Bulls Say, Bears Say
Bulls Say
Business PrioritiesThe collaboration with SNY focused on the exclusive development of IgM agonist antibodies against inflammatory and autoimmune targets remains a top business priority and is starting to make progress.
CollaborationsThe ongoing collaboration with Sanofi on a different IGM molecule is still active and may generate potential future milestones or royalties.
Bears Say
Clinical DevelopmentThe company discontinued all clinical development of its autoimmune franchise due to insufficient efficacy in meeting the required benchmarks.
Stock DowngradeThe decision to discontinue all further development of IgM-based T cell engager programs in autoimmune diseases has led to a downgrade of IGMS shares to Hold-rated.
Workforce ReductionA significant reduction in workforce by 73% was implemented to preserve cash resources.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IGMS FAQ
What was IGM Biosciences Inc’s price range in the past 12 months?
IGM Biosciences Inc lowest stock price was $1.15 and its highest was $22.50 in the past 12 months.
What is IGM Biosciences Inc’s market cap?
IGM Biosciences Inc’s market cap is $73.52M.
When is IGM Biosciences Inc’s upcoming earnings report date?
IGM Biosciences Inc’s upcoming earnings report date is Mar 27, 2025 which is yesterday.
How were IGM Biosciences Inc’s earnings last quarter?
IGM Biosciences Inc released its earnings results on Nov 08, 2024. The company reported -$1.01 earnings per share for the quarter, missing the consensus estimate of -$0.8 by -$0.21.
Is IGM Biosciences Inc overvalued?
According to Wall Street analysts IGM Biosciences Inc’s price is currently Undervalued.
Does IGM Biosciences Inc pay dividends?
IGM Biosciences Inc does not currently pay dividends.
What is IGM Biosciences Inc’s EPS estimate?
IGM Biosciences Inc’s EPS estimate is -0.64.
How many shares outstanding does IGM Biosciences Inc have?
IGM Biosciences Inc has 34,388,420 shares outstanding.
What happened to IGM Biosciences Inc’s price movement after its last earnings report?
IGM Biosciences Inc reported an EPS of -$1.01 in its last earnings report, missing expectations of -$0.8. Following the earnings report the stock price went down -9.325%.
Which hedge fund is a major shareholder of IGM Biosciences Inc?
Currently, no hedge funds are holding shares in IGMS
---
IGM Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.18 (77.24% Upside)
$2.18 (77.24% Upside)
Blogger Sentiment
Bearish
IGMS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $27.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.82%
12-Months-Change
Fundamentals
Return on Equity
-155.76%
Trailing 12-Months
Asset Growth
-37.24%
Trailing 12-Months
Company Description
IGM Biosciences Inc
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
---
IGMS Stock 12 Month Forecast
Average Price Target
$2.18
▲(77.24% Upside)
Technical Analysis
Best Analysts Covering IGMS
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+26.93%
reiterated a sell rating 21 days ago
Copying Michael Ulz's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +26.93% per trade.
---